Micelle BioPharma is an integrated specialty pharmaceutical company. We are uniquely focused on diseases that impact fatty acid balance within the body and we have developed Advanced Lipid Technologies® (ALT®) to increase bioavailability of lipids and lipophilic materials while minimizing the effects of food on the absorption of these materials or the impact of the liver on their delivery to the target sites of therapeutic action within body.

Our most advanced applications of ALT include:

Sickle Cell Disease* (SC411) – Our pediatric soft gelatin capsule formulation to treat vaso-occlusive crises in Sickle Cell Disease
Severe Hypertriglyceridemia (SC401) – An ALT super bioavailable formulation has been shown to reduce triglycerides by over 40% with a lower dose of Omega-3 fatty acids within 14 days. The formulation can be taken with or without food.
Pediatric Malabsorption* in Short Bowel Syndrome (SC403) – Our formulation that can used with enteral feeding to reduce the need for parenteral nutrition
* Orphan Drug Status granted by the U.S. FDA in 2015

If you want to learn more about opportunities to invest with us send us a note and one of our team will reach out to you and schedule time to talk.